Torrent Pharma, with annual income of greater than ₹8,500 crores, is the flagship firm of the Torrent Group. It’s ranked eighth within the Indian Prescription drugs Market and is amongst the highest 5 within the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI),Central Nervous System (CNS), and Nutritional vitamins Minerals Nutritionals (VMN).
For the January-March quarter of 2022, Torrent Pharma reported a internet lack of ₹118 crore attributable to headwinds confronted by its EU enterprise and discontinuation of its liquids enterprise within the U.S. The corporate had posted a revenue after tax of ₹324 crore within the corresponding quarter of final 12 months. Its income rose 10% YoY to ₹2,131 crore, supported by progress in branded generic markets.
The corporate’s board has declared a closing dividend of ₹23 (460%) per share of ₹5 every together with a particular dividend of ₹15 per share. It additionally accepted the problem of bonus shares within the ratio of 1: 1 for every absolutely paid up fairness share held as on file date mounted for the aim. Consequent to the bonus situation, the entire paid up share capital will probably be Rs. 169.22 crore from the present Rs. 84.62 crore.
Apart from, the board additionally gave nod to issuance of fairness shares together with convertible bonds/ debentures via certified institutional placement (QIP) and / or depository receipts or another modes for an quantity as much as ₹5,000 crore, topic to approval within the upcoming annual common assembly of the corporate.